IN8bio Updates Clinical Data for INB-200 and INB-400

IN8bio announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies at the 2026 American Society of Clinical Oncology, or ASCO, annual meeting. Among patients who received up to six repeat doses of genetically modified gamma delta T cells, median progression-free survival reached 13 months, nearly double the 6.6 months observed in patients receiving standard-of-care alone. mOS has not yet been reached in repeat-dose patients and currently exceeds 19.5 months, compared to a final mOS of 13.2 months for patients receiving only SOC. Approximately 43% of repeat-dose patients remained alive at 24 months versus only 20% of SOC patients. Data are as of the May 15 data cutoff. The studies demonstrated that intracranially delivered DeltEx DRI was generally well tolerated, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity events reported. Additional translational analyses integrating histopathology with artificial intelligence technology demonstrated that DeltEx DRI treatment drove a cold-to-hot tumor microenvironment shift, with broad T cell infiltration and reduction in immunosuppressive granulocytes not observed in SOC patients. Repeat DeltEx DRI dosing resulting in higher total doses also increased cumulative T cell and CD4+ levels that correlated significantly with overall survival, linking sustained immune reconstitution to improved outcomes in a dose-dependent manner. Taken together these data point to a T cell-mediated local mechanism with systemic reach.